Skip to main content
Midas Edge

IOVANCE BIOTHERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

IOVA$8.17+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Balance Sheets

(In thousands, except share and per share information)

​​​​​​​
​ · ​ ​ ​ · December 31, · ​ · December 31,
​ · ​ ​ ​ · 2025 · ​ ​ ​ · 2024
ASSETS · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​
Current Assets · ​ · ​ · ​ · ​ · ​
Cash and cash equivalents​$163,078$115,694
Trade accounts receivable​​82,448​69,340
Short-term investments​133,902208,087
Inventory​​51,678​51,520
Prepaid expenses and other assets​11,58312,377
Total Current Assets​442,689457,018
​​​​
Property and equipment, net​​131,112​109,081
Intangible assets, net​​279,324​282,398
Operating lease right-of-use assets​​45,899​55,201
Restricted cash​​5,980​6,359
Long-term assets​8,166369
Total Assets​$913,170$910,426
​​​​
LIABILITIES AND STOCKHOLDERS’ EQUITY​​​
​​​​
Current Liabilities​​​
Accounts payable​$22,159$27,509
Accrued expenses and other liabilities​111,15681,936
Note payable - current​​1,000​​—
Operating lease liabilities​​4,043​12,896
Total Current Liabilities​138,358122,341
​​​​
Non-Current Liabilities​​​
Operating lease liabilities – non-current​44,40144,365
Deferred tax liabilities​​31,828​32,315
Long-term note payable​​—​1,000
Total Non-Current Liabilities​76,22977,680
Total Liabilities​214,587200,021
​​​​
Commitments and contingencies​​​
​​​​
Stockholders’ Equity​​​
Series A Convertible Preferred stock, $0.001 par value; 17,000 shares designated, 194 shares issued and outstanding as of December 31, 2025 and December 31, 2024​——
Series B Convertible Preferred stock, $0.001 par value; 11,500,000 shares designated, 1,932,667 and 2,842,158 shares issued and outstanding as of December 31, 2025 and December 31, 2024 respectively​23
Common stock, $0.000041666 par value; 500,000,000 shares authorized, 411,938,061 and 305,252,194 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively​1713
Accumulated other comprehensive income (loss)​16,440(1,046)
Additional paid-in capital​3,457,6543,095,987
Accumulated deficit​(2,775,530)(2,384,552)
Total Stockholders’ Equity​698,583710,405
Total Liabilities and Stockholders’ Equity​$913,170$910,426
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.